Bionano Genomics, Inc (BNGO) Fair Value & Analysis
Healthcare · US · Market cap $13.5M
Bionano Genomics, Inc
BNGO · US
Fair value as of: Jul 15, 2026
From 1 valuation models · updated today
Fair value updated Jul 15, 2026 — revised from $17.42 to $1.41 (−91.9%) since Jun 24, 2026. Share price −0.9% over the past month.
Price vs Fair Value (12 months)
12‑month range $1.09 – $4.92 · fair‑value band $0.9300 – $1.77 · the $1.15 price screens below the $1.41 fair value. As of Jul 15, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Bionano Genomics, Inc (BNGO) currently trades at $1.15, while our model-based Fair Value estimate is $1.41 — implying the stock looks roughly 22.6% undervalued today. We read business quality at 22/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Trailing-twelve-month revenue stands at $28.7M. Revenue grew 3.6% year over year. It earns a return on equity of -73.8%. Net debt stands at $3.9M. Fundamentals as of Jul 15, 2026
Our scenario range runs from $0.9300 (bear case) to $1.77 (bull case); at $1.15, the current price sits within that range. The share trades about 79% below its 52-week high and 8% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -16% fair-value upside — at 23%, BNGO screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 15, 2026. TTM = trailing twelve months.
About the company
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Bionano Genomics, Inc reported revenue of $28.5M in FY2025 versus $18.0M in FY2021, a compound +12.2%/yr. Reported net income was −$26.4M in FY2025.
Is BNGO fairly valued? → Check now
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.95 | $182.39 | -55% |
| EssilorLuxottica Société anonyme ESLOF | $205.86 | $114.90 | -44% |
| HOYA Corporation HOCPY | $168.16 | $96.16 | -43% |
| Medline Inc MDLN | $34.71 | $30.15 | -13% |
| Becton, Dickinson and Company BDX | $147.79 | $124.26 | -16% |
| Alcon Inc ALC | CHF 52.78 | CHF 46.31 | -12% |
| ResMed Inc RMD | $196.04 | $185.14 | -6% |
| West Pharmaceutical Services, Inc WST | $329.71 | $137.28 | -58% |
| Terumo Corporation TRUMF | $14.62 | $12.65 | -13% |
| Straumann Holding SAUHY | $13.07 | $5.51 | -58% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Bionano Genomics, Inc (BNGO) undervalued?
What is the fair value of BNGO?
What is the quality score of BNGO?
What is the revenue of Bionano Genomics, Inc (BNGO)?
What is the net profit margin of BNGO?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full Bionano Genomics, Inc analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.